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Background/aim: The aim of this study is to evaluate the distribution, sources, clinical features, and mortality rates of bacteremia due
to evaluation of extensively drug-resistant (XDR) gram negative among solid-organ transplant (SOT) recipients.
Materials and methods: A retrospective study of SOT recipients with bacteremia due to XDR gram-negative pathogens in 11 centers
between 2016 and 2018 was conducted. Patients’ records were evaluated.
Results: Of 171 bacteremia that occurred in 164 SOT recipients, 93 (56.7%) were liver, 46 (28%) kidney, 14 (8.5%) heart, and 11 (6.7%)
lung recipients. Bacteremia episodes were recorded in the first year in 63.7% of the patients (n = 109), early-onset bacteremia was
recorded in 45% (n = 77) of the episodes. In multivariate analysis, catheter-associated bacteremia was an independent risk factor for
7-day mortality (p = 0.037), and early-onset bacteremia was found as an independent risk factor for 30-day mortality (p = 0.017).
Conclusion: Difficult-to-treat infections due to XDR bacteria in SOT recipients shadow the success of transplantation. Central venous
catheters seem to be the main risk factor. Judicious use of medical devices is of pivotal importance.
Key words: Solid-organ transplant recipients, drug-resistant, bacteremia

1. Introduction
Infections are still the most important cause of
morbidity and mortality in solid-organ transplant
(SOT) recipients despite advances in surgical
techniques, immunosuppressive therapies, and
infection-control precautions. Transplant recipients are
at risk for various pathogens including opportunistic
infections, reactivation of latent microorganisms,

donor-mediated infections and healthcare-associated
infections [1].
Bacteremia occurs in 5%–10% of kidney transplant
and heart transplant recipients and more commonly in
liver transplant and lung transplant recipients with rates of
10%–25%. The sources of bacteremia may include centralline catheters, the pulmonary tract, the urinary tract, and
the surgical site [2].
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Significantly, recent reports have shown a shift towards
gram-negative bacteria (GNB) in the distribution of the
pathogens that cause bloodstream infection (BSI) in the
SOT recipients [3–6].
The incidence of GNB BSIs is reported to be 210.3/1000
person-years in the first month after transplantation and
decreased to 25.7/1000 person-years between 2 and 12
months after transplantation [7]. The incidence of septic
shock in patients who have gram-negative bacteremia
is reported to be higher than in those with either grampositive or fungal infections [8].
Growing antimicrobial resistance is another concern
in SOT recipients. Frequent or prolonged hospitalization,
exposure to multiple invasive procedures or to indwelling
devices and the use of multiple antimicrobial drugs all
put patients at high risk of colonization and infection
with multiple drug-resistant (MDR) bacteria. Managing
infections caused by these pathogens is very difficult.
Controlling MDR or extensively drug-resistant (XDR)
bacteremia in immunosuppressive patients is a further
challenge for clinicians. There is no specific prevention or
treatment proposal.
The aim of this study is to evaluate the distribution of
the etiological agents of XDR GNB BSIs and the clinical
features of early- and late-onset XDR GNB BSIs along with
7- and 30-day mortality rates among SOT recipients.
2. Materials and methods
2.1. Data collection
We conducted a retrospective study of SOT recipients
of who had XDR GNB bacteremia in 11 centers (from
Ankara, Malatya, İstanbul, Adana, İzmir, Denizli, Antalya)
in Turkey between December 1, 2016 and December
31,2018. All patients were over 18 years of age.
Demographic, clinical and laboratory data were
collected retrospectively from the patients’ medical
records and age, sex, type and date of transplant, date
of BSI episode, microbiological characteristics, source
of infection, and laboratory tests, and 7-day and 30-day
mortality rates were recorded.
Comorbidities
included
diabetes
mellitus,
cardiovascular diseases, chronic kidney disease, chronic
liver disease, and chronic pulmonary diseases.
This study was approved by the Başkent University
Institutional Review Board (Project number: 94603339604.01.02/20011).
The study evaluated demographic and microbiological
characteristics, laboratory data, early- and late-onset XDR
GNB BSI attacks, and 7- day and 30-day mortality rates.
2.2. Definitions
Early-onset bacteremia is defined as bacteremia that
develops within 30 days after transplantation. Late-onset
bacteremia is defined as bacteremia that develops more

than 30 days after transplantation. Extensively drugresistant (XDR) is defined as bacteria susceptible to only
one or two antibiotics tested according to EUCAST criteria
[9].
2.3. Statistical analysis
All categorical data were reported as number (percentage)
or numeric data as mean ± standard deviation or median
(range). Categorical variables were compared using
Pearson’s χ2 test. To determine the association between
demographic/clinical variables and MDR GNB-related
7- and 30-day mortalities, all covariables associated with
a p-value of <0.05 in the univariate analysis were selected
for multivariate logistic regression analysis. The odds
ratios (ORs) that had 95% confidence intervals (CIs) for
the effect of the demographic and clinical predictors on
mortality were evaluated using logistic regression.
The continuous numerical variables were not normally
distributed, so they were presented as the median values
compared using the Mann–Whitney U test. The categorical
data were presented with frequency (%) and compared
using a chi-square test.
3. Results
During the study period, 171 bacteremia episodes in 164
patients were recorded in 11 centers. Of these patients, 93
(56.7%) were liver, 46 (28%) were kidney, 14 (8.5%) were
heart, and 11 were (6.7%) lung recipients.
Of the 164 patients, 110 (67.3%) were male and the
median age of all patients at the time of the bacteremia
episode was 51 years (min 19, max 74). Table 1 shows the
patients’ demographic characteristics.
Hospitalization within the previous three months
ranged from 0 to 7 times (median 1) and hospitalizations
within the previous year ranged from 0 to 22 times
(median 2).
Antibiotic use during the previous 30 days was
recorded in 105 (61.4%) of the BSI episodes. In 57 of
these cases (33.3%), multiple antibiotics were used.
The distribution of the antibiotics previously used were
carbapenems in 62 (36.5%), piperacillin-tazobactam in 21
(12.4%), cephalosporin in 20 (11.8%), glycopeptide in 19
(11.2%), linezolid in 15 (8.8%), colistin in 15 (8.8%), and
quinolones in 12 (7.1%) patients.
Bacteremia episodes occurred in 63.7% of the patients
(n = 109) in the first year after transplantation, 17.5% (n
= 30) in the second year, 7% (n = 12) in the third year,
and 1.8% (n = 3) in the fourth year. The data showed a
year-by-year decline. Early-onset bacteremia was found in
45% (n=77) of the episodes. Table 2 shows the clinical and
microbiological characteristics of the attacks.
The distribution of isolated bacteria was as follows:
69 episodes (40.4%) Klebsiella pneumoniae, 59 (34.5%)
Acinetobacter baumannii, 20 (11.7%) Escherichia coli,
18 (10.5%) Pseudomonas aeruginosa, and 5 (2.9%)
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Table 1. Clinical and demographic characteristics of patients.
Characteristics

Value

Male/female

110/54

Median age

51 (min 19, max 74)

The type of transplantation

Patient		

BSI attack

Liver

93 (56.7%)

98 (57.3%)

Kidney

46 (28%)		

48 (28.1%)

Heart

14 (8.5%)		

14 (8.2%)

Lung

11 (6.7%)		

11 (6.4%)

The type of donor
Living

88 (53.6%)

Deceased

76 (46.3%)

Comorbidity
None

57 (34.8%)

One

59 (36%)

Multiple

48 (29.3%)

Hospitalization

Median value (range)

Last 3 months

1 (min 0, max 7)

Last 12 months

2 (min 0, max 22)

BSI attack posttransplantation time
0–12 months

109 (63.7%)

13–24 months

30 (17.5%)

25–36 months

12 (7%)

37–48 months

3 (1.8%)

49–60 months

5 (2.9%)

≥61 months

12 (7%)

Antibiotic usage 30 days before BSI
None

66 (38.9%)

Antibiotic usage

105 (61.4%)

One group antibiotic

47 (28.1%)

Multigroup antibiotics

57 (33.3%)

BSI: Bloodstream infection

Enterobacter spp. In addition, 14 (8.2%) episodes were
polymicrobial. The distribution of isolated bacteria
according to transplanted organ is presented in Table 3.
The sources of the bacteremia were as follows: 67
(39.2%) the surgical site, 40 (23.4%) urinary tract, 26
(15.2%) central-line catheters, 19 (11.1%) respiratory
tract, and 15 (8.8%) intraabdominal collections. The
source of the infection was not recorded in four patients.
The distribution of bacteremia sources according to
transplanted organ is presented in Table 4.
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The rate of 30-day mortality after bacteremia was
26.3% (n = 45), and 68.8% (31/45) of these deaths occurred
within the first 7 days.
When we compared the data by the time of the
bacteremia onset, the rate of early-onset bacteremia
was higher in recipients of lung transplantation (81.8%,
9/11) and heart transplantation (64.3%, 9/14); the rate
of late-onset bacteremia was higher in recipients of liver
transplantation (58.2%, 57/98) and kidney transplantation
(62.5%, 30/48) (p = 0.022).
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Table 2. Clinical characteristics of the bacteremia episodes.
İsolated bacteria
Klebsiella pneumoniae

69 (40.4%)

Acinetobacter baumannii

59 (34.5%)

Escherichia coli

20 (11.7%)

Pseudomonas aeruginosa

18 (10.5%)

Enterobacter spp.

5 (2.9%)

Type of organism
Monomicrobial

157 (91.8%)

Polymicrobial

14 (8.2%)

Site of primary infection
Surgical site

67 (39.2%)

Urinary tract

40 (23.4%)

Catheter related

26 (15.2%)

Respiratory tract

19 (11.1 %)

Intraabdominal

15 (8.8%)

Unknown

4 (2.3%)

Time of bacteremia onset
Early-onset (≤30 days posttransplant)

77 (45%)

Late-onset (>30days posttransplant)

94 (55%)

Laboratory values

Mean ± SD (min–max)

Leucocyte (/µL)

11.411 ± 8.200 (100–43.900)

CRP (mg/L)

78.79 ± 86.07 (1.82–467)

Procalcitonin (µg/L)

17.82 ± 28.7 (0.08–100)

CRP: C-reactive protein, SD: standard deviation
Table 3. The distribution of isolated bacteria according to transplanted organ.
Type of
transplantation

Most common

2nd most common

3rd most common

4th most common

Liver (n = 98)

K. pneumoniae (46.9%)

A. baumannii (40.8%)

P. aeruginosa (8.2%)

E. coli (4.1%)

Kidney (n = 48)

K. pneumoniae (37.5%)

E. coli (25 %)

A. baumannii (18.8%)

P. aeruginosa (14.6%)

Heart (n = 14)

A. baumannii (64.3%)

E. coli (21.4 %)

K. pneumoniae (7.1%)

P. aeruginosa (7.1%)

Lung (n = 11)

K. pneumoniae (36.4%)

Enterobacter spp. (27.3%)

P. aeruginosa (18.2%)

E. coli (9.1%)

Transplantation from deceased donors was associated
with an increased rate of early-onset bacteremia: 54.5%
(42/79), while transplantation from living donors was
associated with an increase in late-onset bacteremia: 60.6%
(57/92) (p = 0.048).
The evaluation of the data and laboratory values
according to bacteremia time is presented in Tables 5 and 6.
The highest 7-day mortality rate was found in heart
recipients as 50% (7/14), followed by lung recipients 36.4%

(4/11), kidney recipients 16.7% (8/48), and liver recipients
12.2% (12/98) (p = 0.002).
The 7-day mortality rate was 27.8% (22/79) for those
receiving organs from deceased donors and 9.8% (9/92)
for those receiving organs from living donors (p = 0.002).
The bacteremia in 15 (48.3%) of the 31 patients who died
within 7 days was associated with a central-line catheter
(p < 0.001). The 7-day mortality rate was 26.7% (28/105)
for patients who had used antibiotics for 30 days before
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Table 4. The distribution of bacteremia sources according to transplanted organ.
Type of
Most common
transplantation

2nd most common

3rd most common

4th most common

Liver (n = 98)

Respiratory (12.2%)

Urinary tract (12.2%)

Central-line catheter (9.2%)

Kidney (n = 48) Urinary tract (56.3%)

Surgical site (16.7%)

Central-line catheter (10.4%) Respiratory (6.3%)

Heart (n = 14)

Central-line catheter (50%)

Intraabdominal
collection (28.6%)

Respiratory (14.3%)

Urinary tract (7.1%)

Lung (n = 11)

Central-line catheter (45.5%) Respiratory (18.2%)

Surgical site (18.2%)

Intraabdominal
collection (18.2%)

Surgical site (58.2%)

Table 5. Evaluation of the data according to bacteremia time.
Risk factor

Early-onset bacteremia
n (%)

Late-onset bacteremia
n (%)

The type of transplantation

0.022

Liver

41 (41.8)

57 (58.2)

0.331

Kidney

18 (37.5)

30 (62.5)

0.216

Heart

9 (64.3)

5 (35.7)

Lung

9 (81.8)

2 (18.2)

0.131
0.011

Deceased

42(54.5)

37 (39.4)

Live

35 (45.5)

57 (60.6)

The type of donor

0.048

Site of primary infection

0.663

Surgical site

33 (42.9)

34 (36.2)

0.373

Urinary tract

15 (19.5)

25 (26.6)

0.274

Catheter-related

13 (16.9)

13(13.8)

0.580

Respiratory

7 (9.1)

12(12.8)

0.447

Intraabdominal

8 (10.4)

7 (7.4)

0.499

A. baumanni

29 (37.7)

30 (31.9)

0.432

K. penumoniae

30 (39)

39 (41.5)

0.737

E. coli

7 (9.1)

13 (13.8)

0.337

P. aeruginosa

8 (10.4)

10 (10.6)

0.958

Enterobacter species

3 (3.9)

2 (2.1)

0.495

Polymicrobial

9 (11.7)

5 (5.3)

0.131

Isolated bacteria

0.783

the bacteremia attack and 4.5% (3/66) for those who had
not (p < 0.001). In early-onset bacteremia group, the
7-day mortality rate was 22.1% (17/77), while in late-onset
bacteremia group was 14.8% (14/94) (p = 0.225). In the
multivariate analysis, only catheter-associated infection
was found to be an independent risk factor (p = 0.037) for
7-day mortality.
The highest 30-day mortality rate was 64.3% (9/14)
in patients with heart transplants, followed by those with
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p-value

lung transplants (54.5%, 6/11), renal transplants (22.9%,
11/48), and liver transplants (19.4%, 19/98) (p = 0.001).
The 30-day mortality rate was 39.2% (31/79) in transplant
recipients from deceased donors and 15.2% (14/92) in
transplant recipients from living donors (p < 0.001).
The 30-day mortality rate was 20.7% (12/58) in patients
without comorbidities, 23.3% (14/60) in patients with a
single comorbidity, and 35.8% (19/53) in patients with
multiple comorbidities (p = 0.157). When the 30-day
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Table 6. Evaluation of the laboratory results according to bacteremia time.
Laboratory values

Early-onset bacteremia
Median (min–max)

Late-onset bacteremia
Median (min–max)

p-value

Leucocyte ( /µL)

11100
(100–43900)

10800
(100–40040)

0.379

CRP (mg/L)

29.1
(1.85–320)

54
(1.82–467)

0.085

Procalcitonin (µg/L)

5.5
(0.1–100)

4.7
(0.08–100)

0.420

CRP: C-reactive protein

mortality was evaluated by the source of the bacteremia,
central-line catheters were responsible in 16 (35.5%) of the
46 patients (p < 0.001).
Of the 105 episodes of antibiotic use within the 30 days
before the infection, 39 (37.1%) of these resulted in exitus
(p < 0.001). The 30-day mortality rate was 33.8% (26/77) in
cases of early-onset bacteremia and 20.2% (19/94) in cases
of late-onset bacteremia (p = 0.045).
In the multivariate analysis, bacteremia seen in the first
one month, i.e. early-onset bacteremia, was found as an
independent risk factor for 30-day mortality (p = 0.017).
Table 7 shows the results of 7- and 30- day mortality
univariate and multivariate analysis.
The relationships between 7-day mortality rate and
the median levels of leukocyte, CRP, and procalcitonin
were statistically significant (p = 0.013, 0.003, and 0.019,
respectively). The median levels of CRP and procalcitonin
were higher in patients who experienced mortality within
30 days (p = 0.003 and 0.028, respectively). The analysis of
laboratory values of 7- and 30-day mortality is presented
in Table 8.
4. Discussion
The increasing problem of antimicrobial resistance and
the lack of new treatment options make it difficult to
control infections. This is even more difficult for transplant
patients. SOT recipients were admitted to the emergency
department three times more frequently and were eighteen
times more likely to be exposed to healthcare-associated
infections [10]. The present study revealed hospitalization
within the previous 3 months of BSI ranging from 0 to
7 times (median 1) and within the previous year of BSI
ranging from 0 to 22 (median 2).
In the first 2 months after transplantation, there is a high
risk of infection [11]. In the present study, 63.7% of XDR
GNB BSI occurred in the first year after transplantation.
Patients are at the highest risk for MDR GNB infections
in the early posttransplant period because of the high dose
of immunosuppressive drugs, the frequency of invasive

procedures, and the colonization of resistant bacteria. In
the present study, there were more early posttransplant
infections than late posttransplant ones and mortality was
found to be higher in early-onset bacteremia than in lateonset.
The highest rate of early-onset bacteremia was in lung
transplant patients and the lowest was in kidney transplant
patients. The lack of chance of lung and heart transplant
recipients other than deceased donors may also have
contributed to the increased risk of infection. On the other
hand, these results can be attributed to the fact that kidney
transplants occur in the retroperitoneal region, necessitate
shorter postoperative stays in intensive care units, and
are either less invasive procedures or require shorter
duration. Antibiotic-resistant pathogens are associated
with healthcare environments and transplant patients
frequently receive healthcare services. In the present study,
catheter-associated XDR GNB BSIs were found to be an
independent risk factor for 7-day mortality. This result
emphasizes that catheters should be removed immediately
in cases of catheter-associated infections. On the other
hand, it also points out the importance of infection
prevention measures in the insertion and maintenance
of central-line catheters. Staff training and catheterprotection measures are recommended for this purpose
[12]. The American Society of Transplantation Infectious
Diseases Community MDR GNB Guideline reported
mortality rates of 30%‒50% for carbapenem-resistant
Enterobacteriaceae, 40% for MDR P. aeruginosa, and
greater than 52% for carbapenem-resistant A. baumannii
[11]. In our study we found a 7-day mortality rate of 18.1%
and a 30-day mortality rate of 26.3%. The majority of the
patients in the present study had received liver transplants.
The highest rates of 7- and 30-day mortality were in heart
transplant patients, followed by lung transplant patients,
but the number of heart and lung transplants in our study
is low.
The present study found high rates of late-onset
bacteremia in recipients of transplants from living donors
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Table 7. Comparing the predictors of 7- and 30-day mortality.
Risk factors

7-day mortality

30-day mortality

p-value
OR (%95Cl)
(univariate) (univariate)

Multivariate
p-value

p-value
OR (%95Cl)
(univariate) (univariate)

Gender

0.662

1.2 (0.530–2.718)

0.571

1.23 (0.600–2.523)

Age

0.994

1.02 (0.971–1.032)

0.599

0.99 (0.967–1.019)

The type of transplantation

0.002

Liver

0.021

2.522 (1.134–5.605)

Kidney

0.757

1.15 (0.475–2.784)

Heart

0.001

0.180 (0.058–0.561)

Lung

0.105

0.355 (0.097–1.299)

The type of donor

0.002

3.559 (1.528–8.292)

Polymicrobial

0.290

0.519 (0.152–1.779)

Site of primary infection

<0.001

Surgical site

0.012

3.217 (1.242–8.332)

0.635

Urinary tract

0.014

5.402 (1.229–23.743) 0.309

Catheter-associated

< 0.001

0.091 (0.036–0.232)

Respiratory

0.326

0.578 (0.191–1.744)

Intraabdominal

0.844

0.875 (0.232–3.307)

Antibiotic usage 30 days before BSI

<0.001

0.131 (0.038–0.451)

Bacteremia time

0.225

1.619 (0.740–3.541)

Multivariate
p-value

0.001
0.352
0.452
0.488

0.017

2.300 (1.150–4.600)

0.528

1.285 (0.589–2.805)

0.178

0.001

0.165 (0.052–0.525)

0.689

0.028

0.269 (0.078–0.929)

0.449

< 0.001

3.598 (1.740–7.439)

0.593

0.036

0.319 (0.105–0.968)

0.790

0.002

3.412 (1.518–7.670)

0.309

0.007

4.100 (1.369–12.280) 0.163

< 0.001

0.156 (0.064–0.380)

0.269

0.571 (0.210–1.556)

0.002

0.200 (0.067–0.600)

0.301

< 0.001

0.169 (0.067–0.428)

0.468

0.045

2.012 (1.009–4.013)

0.017

<0.001

0.037

0.180

0.398

BSI: Bloodstream infection
Table 8. Comparing the laboratory values of 7- and 30-day mortality.
7-day mortality

30-day mortality

Yes

No

Yes

No

Laboratory values

Median
(min–max)

Median
(min–max)

p-value
(univariate)

Median
(min–max)

Median
(min–max)

p-value
(univariate)

Leucocyte ( /µL)

8650
(100–28600)

11000
(100–43900)

0.013

11000
(100–40040)

10900
(500–43900)

0.454

CRP (mg/L)

108.5
(3.49–467)

35
(1.8–320)

0.003

84.2
(1.85–467)

33.0
(1.82–320)

0.003

Procalcitonin (µg/L)

11.3
(1.0–86)

4.0
(0.08–100)

0.019

8.0
(0.4–100)

4.0
(0.08–100)

0.028

CRP: C-reactive protein

and high rates of early-onset bacteremia in recipients of
transplants from deceased donors. Donor-type seemed to
be effective in terms of bacteremia prognosis. Qiao et al.
found that deceased donors were significantly related to
mortalities from MDR GNB [3]. In the present study, the
rates of 7- and 30-day mortality were higher in recipients of

1966

organs from deceased donors than in recipients of organs
from living donors. Shields et al. evaluated infections by
XDR A. baumannii in SOT recipients. They reported a 28day clinical success rate of 49% in infected patients, but
44% of those patients had a recurrence within 3 months
[13]. It is well known that achieving success in treatment
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of infections in transplant patients is difficult, but it
becomes much more difficult with XDR bacteria. Because
these patients are very fragile, when infection strikes,
fast and effective empirical antibiotic treatment should
be provided, and the risk of recurrence should be kept in
mind even when the infection is under control.
Studies have reported multiple and inappropriate uses
of antibiotics as risk factors for MDR organisms [14]. In the
present study, the use of antibiotics within 30 days before
the BSI attack was significantly related to higher rates of
both 7- and 30-day mortality; however, after multivariate
analysis, it was not found as an independent risk factor. In
transplant patients, hospitalization is generally preferred
over outpatient treatment. Given this, while the patient’s
current episode of infection is being treated, the hospital
environment may increase the chances of colonization or
infection with resistant bacterial flora. Mazza et al. found
mortality of 100% in patients with carbapenem-resistant
K. pneumoniae colonized before transplantation and
mortality of 60% in patients colonized after transplantation
[15].
The tendency to increase antimicrobial resistance
among GNBs may affect local decisions regarding
empirical antibiotic treatment of transplant patients who
present with possible BSIs. Yeşilkaya et al. found that the
XDR rate for A. baumannii was 38.9% [16]. Therefore, it
is important to know the patient’s colonization status in

order to provide appropriate empirical antibiotic treatment
rather than beginning inappropriate broad-spectrum
antibiotics [17,18].
Limitations of this study are the lack of data on
prospective follow-up of patients, the effectiveness of the
antibacterial treatments, and the attributable mortality
rates regarding bacteremia due to XDR GNB.
Infections—nowadays difficult-to-treat infections due
to XDR bacteria—in SOT recipients shadow the success of
transplantation. In this study, central venous catheters and
antibiotic use seem to be the two main driving main risk
factors for the development of difficult-to-treat bacteremia
caused by XDR GNB. To combat these infections, judicious
use of medical devices is of pivotal importance.
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